Target deconvolution of bioactive small molecules: The heart of chemical biology and drug discovery

Archives of Pharmacal Research

Volumn 38, Issue 9, 2015, Pages 1627-1641

  Jung, Hye Jin ^a   Kwon, Ho Jeong ^b,c  

^a SunMoon University   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Chemical biology; Drug discovery; Small molecule; Target identification

Indexed keywords

AFFINITY CHROMATOGRAPHY; BIOACTIVE SMALL MOLECULE; BIOINFORMATICS; BIOLOGY; CHEMICAL BIOLOGY; CHEMICAL PROCEDURES; DRUG AFFINITY RESPONSIVE TARGET STABILITY; DRUG DEVELOPMENT; DRUG TARGETING; GENETICS; GENOMICS; HUMAN; MOLECULE; MULTIOMICS BASED TARGET IDENTIFICATION AND VALIDATION SYSTEM; NONHUMAN; PHAGE DISPLAY; PROTEOMICS; REVIEW; ANIMAL; DRUG DELIVERY SYSTEM; METABOLISM; MOLECULAR LIBRARY; PHARMACEUTICS; PROCEDURES; SYNTHESIS;

MOLECULAR LIBRARY;

ANIMALS; BIOPHARMACEUTICS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; PROTEOMICS; SMALL MOLECULE LIBRARIES;

EID: 84941992624     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-015-0618-3     Document Type: Review

References (101)

1. Aghajan, M., N. Jonai, K. Flick, F. Fu, M. Luo, X. Cai, I. Ouni, N. Pierce, X. Tang, B. Lomenick, R. Damoiseaux, R. Hao, P.M. Del Moral, R. Verma, Y. Li, C. Li, K.N. Houk, M.E. Jung, N. Zheng, L. Huang, R.J. Deshaies, P. Kaiser, and J. Huang. 2010. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nature Biotechnology 28: 738-742.
2. Aoki, S., K. Morohashi, T. Sunoki, K. Kuramochi, S. Kobayashi, and F. Sugawara. 2007. Screening of paclitaxel-binding molecules from a library of random peptides displayed on T7 phage particles using paclitaxel-photoimmobilized resin. Bioconjugate Chemistry 18: 1981-1986.
3. Apsel, B., J.A. Blair, B. Gonzalez, T.M. Nazif, M.E. Feldman, B. Aizenstein, R. Hoffman, R.L. Williams, K.M. Shokat, and Z.A. Knight. 2008. Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nature Chemical Biology 4: 691-699.
4. Armour, C.D., and P.Y. Lum. 2005. From drug to protein: Using yeast genetics for high-throughput target discovery. Current Opinion in Chemical Biology 9: 20-24.
5. Bantscheff, M., D. Eberhard, Y. Abraham, S. Bastuck, M. Boesche, S. Hobson, T. Mathieson, J. Perrin, M. Raida, C. Rau, V. Reader, G. Sweetman, A. Bauer, T. Bouwmeester, C. Hopf, U. Kruse, G. Neubauer, N. Ramsden, J. Rick, B. Kuster, and G. Drewes. 2007. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nature Biotechnology 25: 1035-1044.
6. Brehm, M.A., M.V. Wiles, D.L. Greiner, and L.D. Shultz. 2014. Generation of improved humanized mouse models for human infectious diseases. Journal of Immunological Methods 410: 3-17.
7. Brissette, R., J.K. Prendergast, and N.I. Goldstein. 2006. Identification of cancer targets and therapeutics using phage display. Current Opinion in Drug Discovery & Development 9: 363-369.
8. Brummelkamp, T.R., A.W. Fabius, J. Mullenders, M. Madiredjo, A. Velds, R.M. Kerkhoven, R. Bernards, and R.L. Beijersbergen. 2006. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nature Chemical Biology 2: 202-206.
9. Carlson, E.E. 2010. Natural products as chemical probes. ACS Chemical Biology 5: 639-653.
10. Castoreno, A.B., Y. Smurnyy, A.D. Torres, M.S. Vokes, T.R. Jones, A.E. Carpenter, and U.S. Eggert. 2010. Small molecules discovered in a pathway screen target the Rho pathway in cytokinesis. Nature Chemical Biology 6: 457-463.
11. Chen, X., M.X. Liu, and G.Y. Yan. 2012. Drug-target interaction prediction by random walk on the heterogeneous network. Molecular BioSystems 8: 1970-1978.
12. Cheng, A.C., R.G. Coleman, K.T. Smyth, Q. Cao, P. Soulard, D.R. Caffrey, A.C. Salzberg, and E.S. Huang. 2007. Structure-based maximal affinity model predicts small-molecule druggability. Nature Biotechnology 25: 71-75.
13. Cheng, K.W., C.C. Wong, M. Wang, Q.Y. He, and F. Chen. 2010. Identification and characterization of molecular targets of natural products by mass spectrometry. Mass Spectrometry Reviews 29: 126-155.
14. Chin, R.M., X. Fu, M.Y. Pai, L. Vergnes, H. Hwang, G. Deng, S. Diep, B. Lomenick, V.S. Meli, G.C. Monsalve, E. Hu, S.A. Whelan, J.X. Wang, G. Jung, G.M. Solis, F. Fazlollahi, C. Kaweeteerawat, A. Quach, M. Nili, A.S. Krall, H.A. Godwin, H.R. Chang, K.F. Faull, F. Guo, M. Jiang, S.A. Trauger, A. Saghatelian, D. Braas, H.R. Christofk, C.F. Clarke, M.A. Teitell, M. Petrascheck, K. Reue, M.E. Jung, A.R. Frand, and J. Huang. 2014. The metabolite α-ketoglutarate extends lifespan by inhibiting ATP synthase and TOR. Nature 510: 397-401.
15. Cho, Y.S., and H.J. Kwon. 2012. Identification and validation of bioactive small molecule target through phenotypic screening. Bioorganic and Medicinal Chemistry 20: 1922-1928.
16. Deshpande, G.P., J. Hayles, K.L. Hoe, D.U. Kim, H.O. Park, and E. Hartsuiker. 2009. Screening a genome-wide S. pombe deletion library identifies novel genes and pathways involved in genome stability maintenance. DNA Repair 8: 672-679.
17. Ericson, E., S. Hoon, R.P. St Onge, G. Giaever, and C. Nislow. 2010. Exploring gene function and drug action using chemogenomic dosage assays. Methods in Enzymology 470: 233-255.
18. Ermakova, S., B.Y. Choi, H.S. Choi, B.S. Kang, A.M. Bode, and Z. Dong. 2005. The intermediate filament protein vimentin is a new target for epigallocatechin gallate. The Journal of biological chemistry 280: 16882-16890.
19. Franceschini, A., D. Szklarczyk, S. Frankild, M. Kuhn, M. Simonovic, A. Roth, J. Lin, P. Minguez, P. Bork, C. von Mering, and L.J. Jensen. 2013. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Research 41(Database issue): D808-D815.
20. Futamura, Y., M. Muroi, and H. Osada. 2013. Target identification of small molecules based on chemical biology approaches. Molecular BioSystems 9: 897-914.
21. Gao, Y., X.C. Lu, H.Y. Yang, X.F. Liu, J. Cao, and L. Fan. 2012. The molecular mechanism of the anticancer effect of atorvastatin: DNA microarray and bioinformatic analyses. International Journal of Molecular Medicine 30: 765-774.
22. Giaever, G., P. Flaherty, J. Kumm, M. Proctor, C. Nislow, D.F. Jaramillo, A.M. Chu, M.I. Jordan, A.P. Arkin, and R.W. Davis. 2004. Chemogenomic profiling: Identifying the functional interactions of small molecules in yeast. Proceedings of the National Academy of Sciences of the United States of America 101: 793-798.
23. Giaever, G., D.D. Shoemaker, T.W. Jones, H. Liang, E.A. Winzeler, A. Astromoff, and R.W. Davis. 1999. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nature Genetics 21: 278-283.
24. Glaab, E., A. Baudot, N. Krasnogor, R. Schneider, and A. Valencia. 2012. EnrichNet: network-based gene set enrichment analysis. Bioinformatics 28: i451-i457.
25. Gray, N.S., L. Wodicka, A.M. Thunnissen, T.C. Norman, S. Kwon, F.H. Espinoza, D.O. Morgan, G. Barnes, S. LeClerc, L. Meijer, S.H. Kim, D.J. Lockhart, and P.G. Schultz. 1998. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281: 533-538.
26. Gygi, S.P., B. Rist, S.A. Gerber, F. Turecek, M.H. Gelb, and R. Aebersold. 1999. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotechnology 17: 994-999.
27. Hidalgo, M., F. Amant, A.V. Biankin, E. Budinská, A.T. Byrne, C. Caldas, R.B. Clarke, S. de Jong, J. Jonkers, G.M. Mælandsmo, S. Roman-Roman, J. Seoane, L. Trusolino, and A. Villanueva. 2014. Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discovery 4: 998-1013.
28. Ho, C.H., L. Magtanong, S.L. Barker, D. Gresham, S. Nishimura, P. Natarajan, J.L. Koh, J. Porter, C.A. Gray, R.J. Andersen, G. Giaever, C. Nislow, B. Andrews, D. Botstein, T.R. Graham, M. Yoshida, and C. Boone. 2009. A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds. Nature Biotechnology 27: 369-377.
29. Hoepfner, D., S. Karkare, S.B. Helliwell, M. Pfeifer, M. Trunzer, S. De Bonnechose, A. Zimmerlin, J. Tao, D. Richie, A. Hofmann, S. Reinker, M. Frederiksen, N.R. Movva, J.A. Porter, N.S. Ryder, and C.N. Parker. 2012. An integrated approach for identification and target validation of antifungal compounds active against Erg11p. Antimicrobial Agents and Chemotherapy 56: 4233-4240.
30. Ito, T., H. Ando, T. Suzuki, T. Ogura, K. Hotta, Y. Imamura, Y. Yamaguchi, and H. Handa. 2010. Identification of a primary target of thalidomide teratogenicity. Science 327: 1345-1350.
31. Jiang, Z., and Y. Zhou. 2005. Using gene networks to drug target identification. Journal of Integrative Bioinformatics 2: 14.
32. Jung, H.J., and H.J. Kwon. 2013. Exploring the role of mitochondrial UQCRB in angiogenesis using small molecules. Molecular BioSystems 9: 930-939.
33. Jung, H.J., J.S. Shim, J. Lee, Y.M. Song, K.C. Park, S.H. Choi, N.D. Kim, J.H. Yoon, P.T. Mungai, P.T. Schumacker, and H.J. Kwon. 2010. Terpestacin inhibits tumor angiogenesis by targeting UQCRB of mitochondrial complex III and suppressing hypoxia-induced reactive oxygen species production and cellular oxygen sensing. The Journal of biological chemistry 285: 11584-11595.
34. Jung, H.J., J.S. Shim, J. Park, H.J. Ha, J.H. Kim, J.G. Kim, N.D. Kim, J.H. Yoon, and H.J. Kwon. 2009. Identification and validation of calmodulin as a binding protein of an anti-proliferative small molecule 3,4-dihydroisoquinolinium salt. Proteomics Clinical Applications 3: 423-432.
35. Kaczorowski, G.J., O.B. McManus, B.T. Priest, and M.L. Garcia. 2008. Ion channels as drug targets: The next GPCRs. The Journal of General Physiology 131: 399-405.
36. Kanehisa, M., S. Goto, Y. Sato, M. Furumichi, and M. Tanabe. 2012. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Research 40(Database issue): D109-D114.
37. Kanoh, N., K. Honda, S. Simizu, M. Muroi, and H. Osada. 2005. Photo-cross-linked small-molecule affinity matrix for facilitating forward and reverse chemical genetics. Angewandte Chemie International Ed in English 44: 3559-3562.
38. Kawatani, M., H. Okumura, K. Honda, N. Kanoh, M. Muroi, N. Dohmae, M. Takami, M. Kitagawa, Y. Futamura, M. Imoto, and H. Osada. 2008. The identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I. Proceedings of the National Academy of Sciences of the United States of America 105: 11691-11696.
39. Keiser, M.J., V. Setola, J.J. Irwin, C. Laggner, A.I. Abbas, S.J. Hufeisen, N.H. Jensen, M.B. Kuijer, R.C. Matos, T.B. Tran, R. Whaley, R.A. Glennon, J. Hert, K.L. Thomas, D.D. Edwards, B.K. Shoichet, and B.L. Roth. 2009. Predicting new molecular targets for known drugs. Nature 462: 175-181.
40. Kelly, W.K., and P.A. Marks. 2005. Drug insight: histone deacetylase inhibitors - Development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nature Clinical Practice Oncology 2: 150-157.
41. Kim, D.U., J. Hayles, D. Kim, V. Wood, H.O. Park, M. Won, H.S. Yoo, T. Duhig, M. Nam, G. Palmer, S. Han, L. Jeffery, S.T. Baek, H. Lee, Y.S. Shim, M. Lee, L. Kim, K.S. Heo, E.J. Noh, A.R. Lee, Y.J. Jang, K.S. Chung, S.J. Choi, J.Y. Park, Y. Park, H.M. Kim, S.K. Park, H.J. Park, E.J. Kang, H.B. Kim, H.S. Kang, H.M. Park, K. Kim, K. Song, K.B. Song, P. Nurse, and K.L. Hoe. 2010. Analysis of a genome-wide set of gene deletions in the fission yeast Schizosaccharomyces pombe. Nature Biotechnology 28: 617-623.
42. Kim, B.S., K. Lee, H.J. Jung, D. Bhattarai, and H.J. Kwon. 2015. HIF-1α suppressing small molecule, LW6, inhibits cancer cell growth by binding to calcineurin b homologous protein 1. Biochemical and Biophysical Research Communications 458: 14-20.
43. Kitano, H. 2007. A robustness-based approach to systems-oriented drug design. Nature Reviews Drug Discovery 6: 202-210.
44. Knight, Z.A., H. Lin, and K.M. Shokat. 2010. Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer 10: 130-137.
45. Kotake, Y., K. Sagane, T. Owa, Y. Mimori-Kiyosue, H. Shimizu, M. Uesugi, Y. Ishihama, M. Iwata, and Y. Mizui. 2007. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nature Chemical Biology 3: 570-575.
46. Kwon, H.J. 2006. Discovery of new small molecules and targets towards angiogenesis via chemical genomics approach. Current Drug Targets 7: 397-405.
47. Liu, J., J.D. Jr, W.S. Farmer, J. Lane, I.Weissman Friedman, and S.L. Schreiber. 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66: 807-815.
48. Lomenick, B., R. Hao, N. Jonai, R.M. Chin, M. Aghajan, S. Warburton, J. Wang, R.P. Wu, F. Gomez, J.A. Loo, J.A. Wohlschlegel, T.M. Vondriska, J. Pelletier, H.R. Herschman, J. Clardy, C.F. Clarke, and J. Huang. 2009. Target identification using drug affinity responsive target stability (DARTS). Proceedings of the National Academy of Sciences of the United States of America 106: 21984-21989.
49. Lomenick, B., R.W. Olsen, and J. Huang. 2011. Identification of direct protein targets of small molecules. American Chemical Society Chemical Biology 6: 34-46.
50. Low, W.K., Y. Dang, S. Bhat, D. Romo, and J.O. Liu. 2007. Substrate-dependent targeting of eukaryotic translation initiation factor 4A by pateamine A: Negation of domain-linker regulation of activity. Chemistry & Biology 14: 715-727.
51. Luesch, H. 2006. Towards high-throughput characterization of small molecule mechanisms of action. Molecular BioSystems 2: 609-620.
52. Mangalam, A.K., G. Rajagopalan, V. Taneja, and C.S. David. 2008. HLA class II transgenic mice mimic human inflammatory diseases. Advances in Immunology 97: 65-147.
53. Masoudi-Nejad, A., Z. Mousavian, and J.H. Bozorgmehr. 2013. Drug-target and disease networks: Polypharmacology in the post-genomic era. In Silico Pharmacology 1: 17.
54. Matsuyama, A., R. Arai, Y. Yashiroda, A. Shirai, A. Kamata, S. Sekido, Y. Kobayashi, A. Hashimoto, M. Hamamoto, Y. Hiraoka, S. Horinouchi, and M. Yoshida. 2006. ORFeome cloning and global analysis of protein localization in the fission yeast Schizosaccharomyces pombe. Nature Biotechnology 24: 841-847.
55. Moni, M.A., H. Xu, and P. Liò. 2015. CytoCom: A Cytoscape app to visualize, query and analyse disease comorbidity networks. Bioinformatics 31: 969-971.
56. Morris, G.M., R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson. 2009. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry 30: 2785-2791.
57. Nishi, K., M. Yoshida, D. Fujiwara, M. Nishikawa, S. Horinouchi, and T. Beppu. 1994. Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. The Journal of biological chemistry 269: 6320-6324.
58. Nishimura, S., Y. Arita, M. Honda, K. Iwamoto, A. Matsuyama, A. Shirai, H. Kawasaki, H. Kakeya, T. Kobayashi, S. Matsunaga, and M. Yoshida. 2010. Marine antifungal theonellamides target 3beta-hydroxysterol to activate Rho1 signaling. Nature Chemical Biology 6: 519-526.
59. Oda, Y., T. Owa, T. Sato, B. Boucher, S. Daniels, H. Yamanaka, Y. Shinohara, A. Yokoi, J. Kuromitsu, and T. Nagasu. 2003. Quantitative chemical proteomics for identifying candidate drug targets. Analytical Chemistry 75: 2159-2165.
60. Ong, S.E., B. Blagoev, I. Kratchmarova, D.B. Kristensen, H. Steen, A. Pandey, and M. Mann. 2002. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Molecular and Cellular Proteomics 1: 376-386.
61. Ong, S.E., and M. Mann. 2005. Mass spectrometry-based proteomics turns quantitative. Nature Chemical Biology 1: 252-262.
62. Ong, S.E., M. Schenone, A.A. Margolin, X. Li, K. Do, M.K. Doud, D.R. Mani, L. Kuai, X. Wang, J.L. Wood, N.J. Tolliday, A.N. Koehler, L.A. Marcaurelle, T.R. Golub, R.J. Gould, S.L. Schreiber, and S.A. Carr. 2009. Identifying the proteins to which small-molecule probes and drugs bind in cells. Proceedings of the National Academy of Sciences of the United States of America 106: 4617-4622.
63. Park, J., S. Oh, and S.B. Park. 2012. Discovery and target identification of an antiproliferative agent in live cells using fluorescence difference in two-dimensional gel electrophoresis. Angewandte Chemie International Ed in English 51: 5447-5451.
64. Paschke, M. 2006. Phage display systems and their applications. Applied Microbiology and Biotechnology 70: 2-11.
65. Pierce, S.E., R.W. Davis, C. Nislow, and G. Giaever. 2007. Genome-wide analysis of barcoded Saccharomyces cerevisiae gene-deletion mutants in pooled cultures. Nature Protocols 2: 2958-2974.
66. Piggott, A.M., and P. Karuso. 2004. Quality, not quantity: the role of natural products and chemical proteomics in modern drug discovery. Combinatorial Chemistry & High Throughput Screening 7: 607-630.
67. Piggott, A.M., and P. Karuso. 2008. Rapid identification of a protein binding partner for the marine natural product kahalalide F by using reverse chemical proteomics. ChemBioChem 9: 524-530.
68. Qu, X.A., and D.K. Rajpal. 2012. Applications of Connectivity Map in drug discovery and development. Drug Discovery Today 17: 1289-1298.
69. Roemer, T., J. Davies, G. Giaever, and C. Nislow. 2011. Bugs, drugs and chemical genomics. Nature Chemical Biology 8: 46-56.
70. Ross, P.L., Y.N. Huang, J.N. Marchese, B. Williamson, K. Parker, S. Hattan, N. Khainovski, S. Pillai, S. Dey, S. Daniels, S. Purkayastha, P. Juhasz, S. Martin, M. Bartlet-Jones, F. He, A. Jacobson, and D.J. Pappin. 2004. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Molecular and Cellular Proteomics 3: 1154-1169.
71. Sakamoto, S., Y. Kabe, M. Hatakeyama, Y. Yamaguchi, and H. Handa. 2009. Development and application of high-performance affinity beads: Toward chemical biology and drug discovery. Chemical Record 9: 66-85.
72. Sato, S., Y. Kwon, S. Kamisuki, N. Srivastava, Q. Mao, Y. Kawazoe, and M. Uesugi. 2007. Polyproline-rod approach to isolating protein targets of bioactive small molecules: Isolation of a new target of indomethacin. Journal of the American Chemical Society 129: 873-880.
73. Sato, S., A. Murata, T. Shirakawa, and M. Uesugi. 2010. Biochemical target isolation for novices: Affinity-based strategies. Chemistry & Biology 17: 616-623.
74. Savinov, S.N., and D.J. Austin. 2001. The cloning of human genes using cDNA phage display and small-molecule chemical probes. Combinatorial Chemistry & High Throughput Screening 4: 593-597.
75. Schenone, M., V. Dančík, B.K. Wagner, and P.A. Clemons. 2013. Target identification and mechanism of action in chemical biology and drug discovery. Nature Chemical Biology 9: 232-240.
76. Schmidt, A., I. Forne, and A. Imhof. 2014. Bioinformatic analysis of proteomics data. BMC Systems Biology 8(Suppl 2): S3.
77. Schreiber, S.L. 1998. Chemical genetics resulting from a passion for synthetic organic chemistry. Bioorganic and Medicinal Chemistry 6: 1127-1152.
78. 2+/calmodulin function. Chemistry & Biology 11: 1455-1463.
79. Siolas, D., and G.J. Hannon. 2013. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Research 73: 5315-5319.
80. Sleno, L., and A. Emili. 2008. Proteomic methods for drug target discovery. Current Opinion in Chemical Biology 12: 46-54.
81. Stockwell, B.R. 2004. Exploring biology with small organic molecules. Nature 432: 846-854.
82. Sun, J., Y. Wu, H. Xu, and Z. Zhao. 2012. DTome: A web-based tool for drug-target interactome construction. BMC Bioinformatics 13(Suppl 9): S7.
83. Swinney, D.C., and J. Anthony. 2011. How were new medicines discovered? Nature Reviews Drug Discovery 10: 507-519.
84. Taunton, J., J.L. Collins, and S.L. Schreiber. 1996. Synthesis of natural and modified trapoxins, useful reagents for exploring histone deacetylase function. Journal of the American Chemical Society 118: 10412.
85. Tran, D.T., J. Adhikari, and M.C. Fitzgerald. 2014. Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC)-based strategy for proteome-wide thermodynamic analysis of protein-ligand binding interactions. Molecular and Cellular Proteomics 13: 1800-1813.
86. Ueda, M. 2012. Chemical biology of natural products on the basis of identification of target proteins. Chemistry Letters 41: 658-666.
87. Wacker, S.A., B.R. Houghtaling, O. Elemento, and T.M. Kapoor. 2012. Using transcriptome sequencing to identify mechanisms of drug action and resistance. Nature Chemical Biology 8: 235-237.
88. Walsh, D.P., and Y.T. Chang. 2006. Chemical genetics. Chemical Reviews 106: 2476-2530.
89. Wang, Y., and J. Zeng. 2013. Predicting drug-target interactions using restricted Boltzmann machines. Bioinformatics 29: i126-i134.
90. Wang, J., C.J. Zhang, J. Zhang, Y. He, Y.M. Lee, S. Chen, T.K. Lim, S. Ng, H.M. Shen, and Q. Lin. 2015. Mapping sites of aspirin-induced acetylations in live cells by quantitative acid-cleavable activity-based protein profiling (QA-ABPP). Scientific Reports 5: 7896.
91. Wang, Q., Z. Zhao, J. Shang, and W. Xia. 2014. Targets and candidate agents for type 2 diabetes treatment with computational bioinformatics approach. Journal of Diabetes Research 2014: 763936.
92. Weber, A., A. Casini, A. Heine, D. Kuhn, C.T. Supuran, A. Scozzafava, and G. Klebe. 2004. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. Journal of Medicinal Chemistry 47: 550-557.
93. Wermuth, C.G. 2004. Multitargeted drugs: the end of the "one-target-one-disease" philosophy? Drug Discovery Today 9: 826-827.
94. West, G.M., C.L. Tucker, T. Xu, S.K. Park, X. Han, J.R. Yates III, and M.C. Fitzgerald. 2010. Quantitative proteomics approach for identifying protein-drug interactions in complex mixtures using protein stability measurements. Proceedings of the National Academy of Sciences of the United States of America 107: 9078-9082.
95. Wieghaus, K.A., E.P. Gianchandani, M.A. Paige, M.L. Brown, E.A. Botchwey, and J.A. Papin. 2008. Novel pathway compendium analysis elucidates mechanism of pro-angiogenic synthetic small molecule. Bioinformatics 24: 2384-2390.
96. Xie, L., L. Xie, S.L. Kinnings, and P.E. Bourne. 2012. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annual Review of Pharmacology and Toxicology 52: 361-379.
97. Yamanishi, Y., M. Araki, A. Gutteridge, W. Honda, and M. Kanehisa. 2008. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 24: i232-i240.
98. Yamaoka, M., K. Sato, M. Kobayashi, N. Nishio, M. Ohkubo, T. Fujii, and H. Nakajima. 2005. FR177391, a new anti-hyperlipidemic agent from Serratia. IV. Target identification and validation by chemical genetic approaches. The Journal of Antibiotics 58: 654-662.
99. Yashiroda, Y., A. Matsuyama, and M. Yoshida. 2008. New insights into chemical biology from ORFeome libraries. Current Opinion in Chemical Biology 12: 55-59.
100. Ziegler, S., V. Pries, C. Hedberg, and H. Waldmann. 2013. Target identification for small bioactive molecules: Finding the needle in the haystack. Angewandte Chemie International Ed in English 52: 2744-2792.
101. Zuber, J., J. Shi, E. Wang, A.R. Rappaport, H. Herrmann, E.A. Sison, D. Magoon, J. Qi, K. Blatt, M. Wunderlich, M.J. Taylor, C. Johns, A. Chicas, J.C. Mulloy, S.C. Kogan, P. Brown, P. Valent, J.E. Bradner, S.W. Lowe, and C.R. Vakoc. 2011. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.